Insurers who sell plans in Obamacare marketplaces across 16 states and the District of Columbia have asked regulators to approve a 14% median premium increase for 2027, according to a new Peterson-KFF analysis.
Many Americans are shopping around for affordable options as the cost of health insurance soars. But some who hope to keep the same doctors and medications face a thicket of red tape and disruption after they switch plans.
Thousands of people who had a Medicare drug plan with zero-dollar premiums last year got small premium increases this year — and didn’t know it. They were dropped from their coverage for failing to pay amounts as little as $8, and most can’t get it again until 2027.
Drugmakers provide financial assistance to help patients afford increasingly expensive medications. But some insurers do not count those payments toward a plan’s deductible or out-of-pocket maximum and make patients pay instead.
A work requirement is coming to Medicaid. Sam Whitehead tells WAMU’s “Health Hub” how to keep your coverage — and who’s exempt from the new rule.
California’s next governor will face tough decisions on a highly controversial piece of healthcare policy: what to do about health coverage for the more than 1.4 million low-income residents without legal status. Democrat Xavier Becerra and Republican Steve Hilton present starkly different choices as public opinion wavers.
KFF Health News journalists made the rounds on national and local media recently to discuss topical stories. Here’s a collection of their appearances.
From screwworm to flesh-eating bacteria, mounting public health risks are emerging in the wake of deep cuts to federal health agencies and programs.
Join the conversation as the HealthQ team explores the messiness, humor, and satisfaction that comes with caregiving when you’re sandwiched between aging parents and growing kids.
When makers of infant formula hear that babies got sick or died while using their products, what happens next is left largely to the manufacturers. They decide whether to inform the FDA about possible harm, which could trigger steps to protect the public.
